EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Qualitative Assessment of Health-Related Quality of Life Impacts Associated with Sickle Cell Disease in the United States and United Kingdom

Jennifer Drahos iD, Adriana Boateng-Kuffour, Melanie Calvert, Ashley Valentine, Anthony Mason, Nanxin Li, Zahra Pakbaz, Farrukh Shah, Antony P Martin

Advances in Therapy · 2025-02 · 42 (2) · 863-885

DOI: 10.1007/s12325-024-03038-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Therapy, online erschienen am 16.12.2024. Verfasst von Jennifer Drahos und 8 weiteren Autor:innen. Beteiligte Einrichtung: Vertex Pharmaceuticals Incorporated, Boston, MA, USA. Jennifer_Drahos@vrtx.com. Hauptthemen laut MEDLINE: Quality of Life, Anemia, Sickle Cell. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Vertex Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Individuals living with sickle cell disease (SCD) commonly report impaired health-related quality of life (HRQoL). However, impacts of SCD on HRQoL and the unmet needs of SCD treatment/management are under-researched. This study characterized the impact of SCD on HRQoL and identified the unmet needs of individuals with SCD. METHODS: Adults with SCD (aged ≥ 18 years) and caregivers of adolescents (aged 12‒17) with SCD in the United States (US) and United Kingdom (UK) participated in one-on-one virtual semi-structured interviews and focus group discussions (hereafter referred to as 'interviews'). Interviews were transcribed and thematically analyzed. RESULTS: Nineteen individuals participated in the study (across five interviews and three focus group discussions), including 18 adults with SCD (United States, n = 11; United Kingdom, n = 7) and one caregiver of an adolescent with SCD (United States). Most participants were female (n = 15). Participants reported negative impacts of SCD on their HRQoL, including the burden of structuring their lives around SCD, due to unpredictable symptoms. They reported negative impacts to psychological health (e.g., depression/low mood and anxiety) and physical health (e.g., chronic pain and fatigue) that affected their social and family life, work, and education, leading to feelings of isolation. Participants expressed concerns about the future, feelings of resentment, and the need for high resilience when facing the barriers/impacts associated with SCD. Many participants reported negative interactions with healthcare professionals, leading to trauma, anxiety, and routine care avoidance. Most participants reported perceived prejudice during routine SCD treatment/management, including being treated as drug-seekers. CONCLUSION: Individuals with SCD experience negative HRQoL impacts, including impacts to daily activities, social and family life, work and education, psychological health, and prejudice/stigma. Our findings highlight significant unmet needs of individuals living with SCD, including alternative treatment options to reduce vaso-occlusive crisis (VOC) frequency and treat fatigue.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeAnemia, Sickle CellHumansFemaleUnited KingdomMaleAdultAdolescentUnited StatesQualitative ResearchMiddle AgedYoung AdultCaregiversFocus GroupsChildInterviews as Topic

Stichwörter der Autor:innen

FatigueFocus groupsHealth-related quality of lifeHemoglobinopathyQualitative interviewsSickle cell diseaseVaso-occlusive crises

Autor:innen und Institutionen

  • Vertex Pharmaceuticals Incorporated, Boston, MA, USA. Jennifer_Drahos@vrtx.com.
  • Health Economics and Outcomes Research, Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA, 02210, USA. Jennifer_Drahos@vrtx.com.
  • Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Centre for Patient-Reported Outcomes Research, University of Birmingham, Birmingham, UK.
  • National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK.
  • NIHR Applied Research Collaboration, West Midlands, University of Birmingham, Birmingham, UK.

ORCID-Profile: Jennifer Drahos

Förderung

  • Vertex Pharmaceuticals

Zitieren

APA

Drahos, J., Boateng-Kuffour, A., Calvert, M., Valentine, A., Mason, A., Li, N., Pakbaz, Z., Shah, F., & Martin, A. P. (2025). Qualitative Assessment of Health-Related Quality of Life Impacts Associated with Sickle Cell Disease in the United States and United Kingdom. Advances in Therapy, 42(2), 863-885. https://doi.org/10.1007/s12325-024-03038-x

Vancouver

Drahos J, Boateng-Kuffour A, Calvert M, Valentine A, Mason A, Li N, et al. Qualitative Assessment of Health-Related Quality of Life Impacts Associated with Sickle Cell Disease in the United States and United Kingdom. Advances in Therapy. 2025;42(2):863-885. doi:10.1007/s12325-024-03038-x

BibTeX
@article{Drahos2025,
  author = {Drahos, Jennifer and Boateng-Kuffour, Adriana and Calvert, Melanie and Valentine, Ashley and Mason, Anthony and Li, Nanxin and Pakbaz, Zahra and Shah, Farrukh and Martin, Antony P},
  title = {Qualitative Assessment of Health-Related Quality of Life Impacts Associated with Sickle Cell Disease in the United States and United Kingdom},
  journal = {Advances in Therapy},
  year = {2025},
  volume = {42},
  number = {2},
  pages = {863--885},
  doi = {10.1007/s12325-024-03038-x}
}
Kostenlos starten →